Page 32 - Read Online

Page 14 of 14 Fujimoto et al. J Cancer Metastasis Treat 2021;7:66 https://dx.doi.org/10.20517/2394-4722.2021.157

advanced natural killer/T cell lymphoma. Signal Transduct Target Ther 2020;5:289. DOI PubMed PMC
79. Du L, Zhang L, Li L, et al. Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for
relapsed/refractory natural killer/T-cell lymphoma: a report of three cases. Onco Targets Ther 2020;13:7189-97. DOI PubMed PMC
80. Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS. Complete remission in CD30-positive refractory extranodal NK/T-cell
lymphoma with brentuximab vedotin. Blood Res 2015;50:254-6. DOI PubMed PMC
81. Poon LM, Kwong YL. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and
bendamustine. Ann Hematol 2016;95:847-9. DOI PubMed
82. Kim SJ, Yoon DH, Kim JS, et al. Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin
lymphomas: results of a multicenter, open-labeled phase II trial. Cancer Res Treat 2020;52:374-87. DOI PubMed PMC
83. Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med
2016;375:1501-2. DOI PubMed
84. Huang H-q, Kim W-S, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory (R/R) natural killer/T-cell
lymphoma (NKTCL), nasal type: updated results from an open-label, single-arm, multicenter phase 2 study. Blood 2019;134:1568.
DOI
85. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory
peripheral T-cell lymphoma. Ann Oncol 2015;26:1766-71. DOI
86. Fujimoto A, Suzuki R. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell
transplantation: pathogenesis, risk factors and clinical outcomes. Cancers (Basel) 2020;12:328. DOI PubMed PMC
87. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T
lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014;32:798-808. DOI PubMed PMC
88. Cho SG, Kim N, Sohn HJ, et al. Long-term outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy
using EBV LMP1 and LMP2a-specific CTLs. Mol Ther 2015;23:1401-9. DOI PubMed PMC
89. Huang Y, de Reyniès A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal
NK/T-cell lymphoma, nasal type. Blood 2010;115:1226-37. DOI PubMed PMC
90. Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell
lymphoma nasal type. Oncotarget 2015;6:17764-76. DOI PubMed PMC
91. Küçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat
Commun 2015;6:6025. DOI
92. Nairismägi ML, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a
novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia 2018;32:1147-56. DOI PubMed PMC
93. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov
2012;2:591-7. DOI PubMed
94. Sim SH, Kim S, Kim TM, et al. Novel JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal type. Am J Pathol
2017;187:980-6. DOI PubMed
95. Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight
JAK-STAT signaling as therapeutic target. Nat Commun 2018;9:1567. DOI PubMed PMC